BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Medilink Midlands - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Medilink Midlands
X-ORIGINAL-URL:https://staging.medilinkmidlands.com
X-WR-CALDESC:Events for Medilink Midlands
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20210401T100000
DTEND;TZID=Europe/London:20210401T113000
DTSTAMP:20260421T181110
CREATED:20210218T140229Z
LAST-MODIFIED:20210218T140229Z
UID:18568-1617271200-1617276600@staging.medilinkmidlands.com
SUMMARY:WEBINAR: Cell Therapies: Bench to Bedside
DESCRIPTION:Cell therapies could be the magic bullet for treating many different and previously intractable diseases. However creating a new cell therapy is fraught with complexities – sourcing\, growing\, transporting cells and other components for these therapies can be difficult. This event in partnership with the Medical Technologies Innovation Facility (MTIF) brings together speakers from charity\, industry and academic sectors to provide considered insights into the different stages of cell therapy development from bench to bedside. \nThe webinar will address: \n• The sustainable and ethical sourcing of human adult derived biological products as starting materials and criteria to consider when selecting the correct starting materials.\n• Translating cell therapy into an implantable medical device with the adoption of substrates and scaffolds.\n• Understanding cellular interactions with substrates and hence need to evaluate in-vitro biocompatibility.\n• Reproducible and robust high throughput in-vitro testing for cell therapy performance validation. \nThere will be an opportunity to ask questions of our presenters in a Q&A session post presentation. \nThis webinar is open to all organisations seeking insight into cell therapy and the practicalities of development for patient use. \nThis free to attend event is held as part of the INSTILS programme – a project part-funded by the European Regional Development Fund\, click here to be re-directed to further information about the project. This event is classed as State Aid to participating businesses\, the value of which is £190\, but is delivered completely free of charge to participants. \nSpeaker Profiles  \n Mike Hannay\, Managing Director\, Medical Technologies Innovation Facility (MTIF) \n(CHAIR) \n  \n  \n  \n  \n Professor John Hunt\, Medical Technologies Innovation Facility (MTIF) \n  \n  \n  \n  \n \nKatie Griffee\, Business Development Manager\, Anthony Noaln Cell & Gene Therapy Services \nKatie supports cell and gene therapy researchers and developers access a scalable source of cellular starting material for R&D through to clinical application. Katie has a BSc in Biomedical Sciences and 7+ years’ experience working with pharmaceutical and biotech companies across Europe and the US. \n  \n  \n  \n \nEmma King\, Sales Engineer\, Hamamatsu Photonics UK Limited \nPresentation: High Throughput Screening (HTS) of stem cells using the Hamamatsu FDSSµcell \nEmma King studied Anatomy\, Developmental and Human Biology at Kings College London\, writing her thesis on cancer cell migration.\nAs part of the Research and Life Science group at Hamamatsu Photonics\, Emma is responsible for business development activities for Functional Drug Screening Systems (FDSS) in the UK. \n  \n  \n  \n \nAnn Kramer\, CEO\, The Electrospinning Company \nAnn Kramer is CEO of The Electrospinning Company\, an SME with a biomaterial platform with applications in regenerative medicine and cell therapy. Ann spent 20 years in agritech multinationals\, then 15 years in UK SMEs including Oxitec\, Immunocore and Biosyntha. \n  \n  \n  \n  \n  \n  \n  \n 
URL:https://staging.medilinkmidlands.com/event/webinar-cell-therapies-bench-to-bedside/
CATEGORIES:Project Event
ATTACH;FMTTYPE=image/jpeg:https://staging.medilinkmidlands.com/wp-content/uploads/2022/04/Emma-King.jpeg
ORGANIZER;CN="Jo Rudzki":MAILTO:info@medilinkem.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20210413T100000
DTEND;TZID=Europe/London:20210413T110000
DTSTAMP:20260421T181110
CREATED:20210127T110543Z
LAST-MODIFIED:20210127T110543Z
UID:18531-1618308000-1618311600@staging.medilinkmidlands.com
SUMMARY:VIRTUAL EVENT: Funding your innovation during lockdown – Speak to the Advisers
DESCRIPTION:We remain open for business during the current lockdown and we will continue to support our members\, clients and the life sciences community\, albeit in a more virtual way. \nHow can our projects help you fund your innovation? Delivered by Medilink Midlands\, join this meeting to meet our team of Advisers for a detailed interactive discussion on innovation grant funding and support. We will talk through examples of the types of projects we can fund and also what other support is available across the East Midlands region. \nDuring this virtual meeting you will: \n-Find out what grant funding is available \n-Find out how we can support you to fast-track your innovations and bring your ideas to market \n-Have the opportunity to ask questions directly to our team of knowledgeable advisers and find out how you can obtain further support \n-Identify who is the dedicated Adviser for your area \n-Receive information on the grants we have available to help companies overcome innovation barriers \nThis is an interactive meeting\, where attendees are encouraged to join via their webcam and to ask questions directly to our advisers. \nDURATION: 1 HOUR \n  \n  \nPLEASE NOTE: The funding and support discussed in this meeting is only available for companies in the East Midlands region. \nThis free to attend meeting will be held as part of the INSTILS programme – a project part-funded by the European Regional Development Fund. Click here to be redirected to further information about the project. This event is classed as State Aid to participating businesses\, the value of which is £127\, but is delivered completely free of charge to participants. \nMedilink Midlands Innovation Advisers:\n    \nLyndsey Allen \n  \n  \n \nNeil Barnes \n  \n  \n  \n  \n  \n \n  \nAlasdair Gaw \n  \n  \n  \n  \n \n  \nJo Maltby \n  \n  \n \n  \nTeresa Smith \n  \n  \n  \n  \n  \n 
URL:https://staging.medilinkmidlands.com/event/innovation-during-lockdown-speak-to-the-advisers/
CATEGORIES:Project Event
ATTACH;FMTTYPE=image/jpeg:https://staging.medilinkmidlands.com/wp-content/uploads/2022/04/erdflogo2.jpg
ORGANIZER;CN="Jo Rudzki":MAILTO:info@medilinkem.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20210421T100000
DTEND;TZID=Europe/London:20210421T110000
DTSTAMP:20260421T181110
CREATED:20210129T140916Z
LAST-MODIFIED:20210129T140916Z
UID:18532-1618999200-1619002800@staging.medilinkmidlands.com
SUMMARY:WEBINAR: Food Supplements Special Interest Group (SIG) - Has Brexit changed how Food Supplements will be managed in 2021?
DESCRIPTION:Join us online for our next Food Supplements Special Interest Group (SIG) to hear about the impact of Brexit on food supplements. \nThis webinar will discuss: \n– What has changed?\n– What has stayed the same?\n– What is new? \nAs well as update\,  we invite our delegates to take part in a question and answer session. \nDURATION: 1 hour \nThis free to attend event is held as part of the INSTILS programme – a project part-funded by the European Regional Development Fund\, click here to be re-directed to further information about the project. This event is classed as State Aid to participating businesses\, the value of which is £127\, but is delivered completely free of charge to participants. \nSpeaker Profiles \nChair: Janet Worrell\, Head of Regulatory\, JensonR+\nJanet is an experienced regulatory affairs professional\, having supported a diverse portfolio of products\, for a number of companies across the East Midlands. Janet’s experience covers early concept development\, food supplements\, over the counter (OTC) medicines\, inhaled therapies and clinical trial applications. Janet enjoys collaborating with companies to develop their regulatory strategy to deliver commercial success. Janet is an independent board member of the East Midlands Academic Health Science Network supporting innovation within NHS. \n  \n  \nNick Bennett\, Head of Product Development\, IVC Brunel Healthcare\nNick is Head of Product Development at Brunel Healthcare\nwhere he is responsible for all aspects of development\, regulations and new product introduction. He has worked in the food supplement industry for over 18 years specialising in all matters relating to product development and the health support that can be delivered from appropriate nutritional supplementation. Nick qualified in Nutritional Biochemistry from Nottingham University in 1994 and has been a Registered Nutritionist since 2003. During this time Nick has worked in a variety of food supplement companies of different sizes\, most recently Boots for 5 years before joining the UK’s number one food supplement manufacturer\, Brunel in 2009. \n  \n 
URL:https://staging.medilinkmidlands.com/event/food-supplements-sig/
CATEGORIES:Project Event
ATTACH;FMTTYPE=image/jpeg:https://staging.medilinkmidlands.com/wp-content/uploads/2022/04/Nick-Bennett-scaled.jpg
ORGANIZER;CN="Jo Rudzki":MAILTO:info@medilinkem.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20210422T100000
DTEND;TZID=Europe/London:20210422T113000
DTSTAMP:20260421T181110
CREATED:20200325T135017Z
LAST-MODIFIED:20200325T135017Z
UID:18579-1619085600-1619091000@staging.medilinkmidlands.com
SUMMARY:WEBINAR: Extended reality applications (virtual\, augmented & mixed reality) in healthcare and surgery
DESCRIPTION:The next Medical Technologies & Systems Special Interest Group (SIG) will take place online\, join us as we discuss Extended reality applications (virtual\, augmented & mixed reality) in healthcare and surgery. \nAttend to hear about:\n– Remote surgical collaboration through Virtual Reality \n– VR as a tool to bridge the gap between academic and clinical practice. The past\, present and the future \n– Mixed Reality – The Future of Surgery Starts Now \nDURATION: 1.5 hours \nThis free to attend event is held as part of the INSTILS programme – a project part-funded by the European Regional Development Fund\, click here to be re-directed to further information about the project.  This event is classed as State Aid to participating businesses\, the value of which is £190\, but is delivered completely free of charge to participants. \nSpeaker Profiles:  \n\nChaired by: Professor Philip Breedon\, Professor of Smart Technologies\, Nottingham Trent University \nAs well as his role at Nottingham Trent University\, Philip is also a Chartered Engineer and a Chartered IT professional. He is a member of the Department of Health’s National Institute for Health Research invention for innovation funding panel and holds a number of journal editorial positions. His research interests and latest projects centre on new and emerging technologies and materials. This includes wearable technologies\, 3D printing of pathological models\, additive and subtractive manufacturing for medical applications\, surgical robotics\, cardiovascular devices\, augmented /virtual/immersive technologies and environments\, the surgical pathway and investigative research related to the utilisation of ‘smart materials’ for medical applications. Through promoting his work and research activities he now works with a number of surgeons and clinicians across Europe. \n\nRichard Vincent\, CEO & Founder\, FundamentalVR\nRichard has 20+ years’ experience of building international businesses and has throughout his career sought opportunities for positive market disruption through technological application.  It was this desire that led him to co-found FundamentalVR to help address an age-old problem for the medical market; how to create safe\, realistic\, measurable spaces to learn and develop skills.  In his role as CEO Richard is responsible for building a world class team of medical\, learning and technologist who together can realise the company’s ambition of creating the world’s first global\, haptically enabled\, low cost ‘flight simulator for surgeons’. \n\nJan Antons\, Business Development Manager\, Vertual Ltd\nJan qualified as a therapy radiographer in 1992 and worked clinically in Bristol before working in various roles in the industry\, including product specialist\, product manager and clinical specialist roles. An MSc in radiotherapy followed in 2008 with a thesis focusing on prostate brachytherapy. After a 2-year placement in the US and experiencing the US Healthcare market\, Jan joined Vertual\, a Hull-based SME\, in 2009 as a product specialist. From 2010 to 2019\, Jan managed a large territory and distribution partners within the assigned regions\, including the UK and Ireland\, the US\, South America and Canada. After completing an MBA in 2019\, Jan started her current role as business development manager. \n\nDr Linda Brützel\, Product Manager\, Brainlab\nLinda is a physicist with expertise in biotechnology and medical science\, currently working as a Product Manager at German medical technology company Brainlab. Linda has a strong background in data analysis\, programming and technical development of experimental setups. After completing her PhD on ‘Structure and Conformational Dynamics of 3D DNA Origami Objects Probed by Small-Angle X-Ray Scattering’ she worked as a Product Manager for PNDetector and as image analysis consultant at Astra Zeneca (formerly known as Definiens).
URL:https://staging.medilinkmidlands.com/event/medical-technologies-systems-special-interest-group-sig-5-reality-apps/
CATEGORIES:Project Event
ATTACH;FMTTYPE=image/png:https://staging.medilinkmidlands.com/wp-content/uploads/2022/04/Richard-Vincent.png
ORGANIZER;CN="Becky Sharpe":MAILTO:events@medilinkmidlands.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20210429T140000
DTEND;TZID=Europe/London:20210429T153000
DTSTAMP:20260421T181110
CREATED:20200922T131336Z
LAST-MODIFIED:20200922T131336Z
UID:18603-1619704800-1619710200@staging.medilinkmidlands.com
SUMMARY:WEBINAR: Bioprinting: from benchside to bedside
DESCRIPTION:Join the next online Additive Manufacturing & 3D Special Interest Group (SIG)\, this SIG will focus on Bioprinting as we hear from an academic\, a clinician and a business as they present what they have learned. \nThis event is in partnership with The University of Nottingham – Centre for Additive Manufacturing. \nThe webinar will cover: \n– The development of smart biomaterials for bioprinting multi-cellular living tissues \n– Translation of bioprinted tissues into clinic\, challenges and opportunities \n– Entrepreneurship in bio-printing: biohybrid neural devices \nDURATION: 1.5 hour \nThis free to attend event is held as part of the INSTILS programme – a project part-funded by the European Regional Development Fund\, click here to be re-directed to further information about the project. This event is classed as State Aid to participating businesses\, the value of which is £190\, but is delivered completely free of charge to participants. \nSpeaker Profiles: \n\nChaired by: Laura Ruiz Cantu\, Transitional Assistant Professor\, Centre for Additive Manufacturing\, The University of Nottingham \nLaura’s research is focused on the use of Additive Manufacturing technologies for Regenerative Medicine and drug delivery applications. Laura has extensive expertise in several AM technologies including micro extrusion printing\, inkjet 3D printing\, micro stereolithography and most recently volumetric additive manufacturing. Some of her work includes\, developing libraries of photocurabe biomaterials for 3D printing subdermal implants\, 3D bioprinting cartilage for facial reconstruction\, developing methodologies for rapid screening of inks and 3D printing of long term subdermal implants for chronic diseases. Currently\, Laura and team are working on developing smart osteoinductive photocurable biomaterials for inkjet printing and microSLA. Laura is also associated to the smart materials HUB from the UK Regenerative Medicine Platform. As part of the HUB she is working on implementing different 3D printing technologies for the manufacture of scaffolds for bone regeneration. \n\nDr Sang Jin Lee\, Associate Professor\, Wake Forest Institute for Regenerative Medicine (WFIRM)\nSang is an Associate Professor of the Wake Forest Institute for Regenerative Medicine (WFIRM)\, Wake Forest School of Medicine\, with an affiliate appointment in the Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences (SBES). The WFIRM is an international leader in translating scientific discovery into clinical therapies. WFIRM were the first in the world to successfully implant a laboratory-grown organ into humans and today are working to grow more than 30 different organs and tissues in the laboratory. He extensive knowledge and experience in biomaterials science\, especially\, biodegradable polymers and tunable hydrogels\, with specific training and expertise in key research areas for tissue engineering and regenerative medicine. His research team has developed various biomaterial systems that improve cellular interactions by providing appropriate environmental cues. These biomaterial systems consist of drug/protein delivery systems\, nano/micro-scaled topographical features\, and hybrid materials that can actively participate in functional tissue regeneration. Recently\, his team is utilizing automated 3D bioprinting technology to manufacture complex\, multi-cellular living tissue constructs that mimic the structure of native tissues. This can be accomplished by optimizing the formulation of biomaterials to serve as bioinks for 3D bioprinting\, and by providing the biological microenvironment needed for the successful delivery of cells and biomaterials to discrete locations within the 3D structure. He has authored more than 150 scientific publications\, 15 patent registrations/applications\, 500 scientific presentations\, 70 invited lectures and mentored over 160 trainees\, ranging from undergraduate students to practicing physicians. \n\nProfessor Paolo De Coppi\, Consultant Paediatric Surgeon\, Great Ormond Street Hospital (GOSH)\nPaolo is a Consultant Paediatric Surgeon at Great Ormond Street Hospital (GOSH) and Head of Stem Cells and Regenerative Medicine at the UCL Institute of Child Health in London. He has been an Honorary Professor at the Katholieke Universiteit Leuven\, Belgium\, since 2013\, an Adjunct Assistant Professor at the Wake Forest Institute for Regenerative Medicine\, Wake Forest University in Winston-Salem\, North Carolina\, since 2009 and an Honorary Assistant Professor in Paediatric Surgery at the University of Padua\, Italy\, since 2005. He has a special interest in congenital malformations and their treatment using minimally invasive techniques. He has focused his research interests on stem cells and tissue engineering by trying to find new modalities for the treatment of complex congenital anomalies. While working with Anthony Atala\, M.D.\, at the Boston Children’s Hospital (Massachusetts)\, he identified the possibility of using stem cells from amniotic fluid for therapeutic applications. This finding generated an international patent and garnered the cover story of Nature Biotechnology January 2007. This finding has opened the door to discovery for novel approaches to correct congenital malformations. Recently he was awarded a WellcomeLeap grant that will be focused on engineering human kidneys and urinary tracts in collaboration with Prof David Long and the kidney development and disease group at UCL. \n\nDr Benjamin Paul\, CEO\, Neuroloom Ltd\nBen founded Neuroloom Ltd in 2017 to commercialise his neurotechnology inventions and has since won multiple competitions and instigated several University and business consortiums. As the sole inventor of Neuroloom’s core patent Ben has presented to academic\, clinical and commercial audiences and has co-authored several academic papers. Before founding Neuroloom\, Ben completed an MSc in Bioengineering and a PhD in Manufacturing at the University of Nottingham. Neuroloom’s expertise is coordinating living neurons so they can reliably integrate with living tissue and coordinate the tissues activity\, whether in the dish or in the body.
URL:https://staging.medilinkmidlands.com/event/webinar-bioprinting-benchside/
CATEGORIES:Project Event
ATTACH;FMTTYPE=image/jpeg:https://staging.medilinkmidlands.com/wp-content/uploads/2022/04/Laura-Ruiz-Cantu.jpg
ORGANIZER;CN="Becky Sharpe":MAILTO:events@medilinkmidlands.com
END:VEVENT
END:VCALENDAR